Relationship between plasma homocysteine levels and saphenous vein graft disease after coronary artery bypass grafts

Japanese Heart Journal

Volumn 42, Issue 5, 2001, Pages 553-562

  Iwama, Yoshitaka ^a   Mokuno, Hiroshi ^a   Watanabe, Yoshiro ^a   Shimada, Kazunori ^a   Yokoi, Hisashi ^a   Daida, Hiroyuki ^a   Hosoda, Yasuyuki ^a   Yamaguchi, Hiroshi ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

Coronary artery bypass graft surgery; Homocysteine; Saphenous vein graft disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; FEMALE; GENE MUTATION; GENOTYPE; GRAFT PATENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SAPHENOUS VEIN GRAFT; STENOSIS; VEIN DISEASE;

CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; GRAFT OCCLUSION, VASCULAR; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; REGRESSION ANALYSIS; RISK FACTORS; SAPHENOUS VEIN; TIME FACTORS;

EID: 0035213327     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.42.553     Document Type: Article

References (37)

1. Progression of atherosclerosis in coronary arteries and bypass grafts: Ten years later
2. Serial angiographic evaluation 1 year and 9 years after aorta-coronary bypass. A study of 55 patients chosen at random
3. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery
4. Atherosclerosis in aorto-coronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery
5. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients
6. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
7. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
8. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease
9. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting
10. Serum total homocysteine and coronary heart disease
11. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis
12. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
13. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke
14. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
15. Hyperhomocysteinemia: An independent risk factor for vascular disease
16. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
17. Vascular pathology of homocysteinemia: Implications for pathogenesis of arteriosclerosis
18. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
19. Clinical and laboratory features of homocystinuria
20. Sulfur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulfide
21. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
22. Fundamental studies on the detection of serum vitamin B12 and folate using chemilumianalyzer ACS-180
23. Semi-automated fluorometric determination of pyridoxal-5′-phosphate (vitamin B6) in whole blood by high-performance liquid chromatography (HPLC)
24. Enzyme-linked immunoassay for Lp(a)
25. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
26. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
27. A reporting system on patients evaluated for coronary artery disease
28. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years
29. Atherosclerosis and late closure of aorto-coronary saphenous vein grafts: Sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery
30. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
31. Homocysteine thiolactone, n-homocysteine thiolactonyl retinamide, and platelet aggregation
32. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator
33. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
34. Mechanisms of thrombosis in hyperhomocysteinemia
35. Pathogenesis of vascular disease in hyperhomocysteinaemia
36. Optimal risk factor management in the patient after coronary revascularization
37. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Investigators